8-K: Collegium Pharma Soars on Record Q3, Boosts 2025 Outlook

Collegium Pharmaceutical, Inc. reported record third-quarter 2025 financial results, driven by strong performance in its ADHD and pain portfolios, leading to a significant raise in its full-year 2025 guidance.

Summary

• Product revenues, net, for Q3 2025 reached a record $209.4 million, a 31% increase year-over-year from $159.3 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was a record $133.0 million, up 27% from $105.1 million in Q3 2024.
• GAAP net income for Q3 2025 was $31.5 million, significantly up from $9.3 million in Q3 2024.
• GAAP diluted earnings per share for Q3 2025 was $0.84, compared to $0.27 in Q3 2024.
• Non-GAAP adjusted net income for Q3 2025 was $87.3 million, with adjusted earnings per share of $2.25.
• Jornay PM net revenue hit $41.8 million in Q3 2025, with prescriptions growing 20% year-over-year and prescribers reaching an all-time high of 27,700 (up 22% year-over-year).
• The pain portfolio generated record net revenue of $167.6 million in Q3 2025, an 11% increase year-over-year, with all three core products (Belbuca, Xtampza ER, Nucynta Franchise) showing growth.
• Belbuca net revenue was $58.3 million (+10% YoY), Xtampza ER net revenue was $50.5 million (+2% YoY), and Nucynta Franchise net revenue was $54.8 million (+21% YoY).
• The company generated $78.4 million in cash from operations during Q3 2025 and ended the quarter with $285.9 million in cash, cash equivalents, and marketable securities.
• Full-year 2025 net revenue guidance was raised to $775-$785 million (from $745-$760 million), and adjusted EBITDA guidance was raised to $460-$470 million (from $440-$455 million).
• Full-year 2025 Jornay PM net revenue guidance was raised to $145-$150 million (from $140-$145 million).
• The Board of Directors authorized a new share repurchase program of up to $150 million through December 31, 2026, and completed a $25 million accelerated share repurchase program in July 2025.

Sentiment

Score: 9

Explanation: The filing reports record financial results, significant year-over-year growth in key metrics (revenue, EBITDA, net income), and a substantial raise in full-year guidance. The company is actively returning value to shareholders through share repurchases and is deleveraging its balance sheet. All core products are growing, and the lead growth driver, Jornay PM, is performing exceptionally well. The only minor negative is the increase in adjusted operating expenses, but this is likely tied to growth investments.

Positives

• Record quarterly net revenue of $209.4 million, up 31% year-over-year.
• Record quarterly Adjusted EBITDA of $133.0 million, up 27% year-over-year.
• Significant increase in GAAP net income and EPS year-over-year.
• Jornay PM net revenue reached a record $41.8 million, with prescriptions growing 20% year-over-year and prescribers increasing by 22%.
• Pain portfolio net revenue achieved a record $167.6 million, growing 11% year-over-year, with all three core products demonstrating growth.
• Raised full-year 2025 net revenue guidance to $775-$785 million, indicating strong future performance expectations.
• Raised full-year 2025 Adjusted EBITDA guidance to $460-$470 million.
• Strong cash generation from operations of $78.4 million in Q3 2025.
• Ended Q3 2025 with a robust cash, cash equivalents, and marketable securities balance of $285.9 million, up $123.1 million from December 2024.
• Net debt to adjusted EBITDA ratio improved to approximately 1.2x at the end of Q3 2025, with an expectation to be below 1.0x by year-end 2025.
• Authorization of a new $150 million share repurchase program and completion of a $25 million accelerated share repurchase program demonstrate commitment to shareholder value.

Negatives

• Adjusted operating expenses increased by 60% year-over-year to $55.7 million in Q3 2025, and full-year guidance was raised to $235-$240 million, indicating higher operational costs.

Risks

• Unknown liabilities could impact financial performance.
• Uncertainty regarding the expected financial performance of products and future market opportunities.
• Challenges in commercializing and growing sales of products.
• Ability to manage relationships with licensors.
• Success of competing products that are or become available.
• Maintaining regulatory approval of products and managing related restrictions, limitations, and/or warnings.
• The size of the markets for products and the ability to service those markets.
• Ability to obtain reimbursement and third-party payor contracts for products.
• The rate and degree of market acceptance of products.
• Costs associated with commercialization activities, including marketing, sales, and distribution.
• Changing market conditions for products.
• Outcome of any patent infringement or other litigation.
• Outcome of any governmental investigation related to the business.
• Ability to secure adequate supplies of active pharmaceutical ingredient and manufacture commercially saleable inventory.
• Ability to obtain funding for operations and business development.
• Regulatory developments in the U.S.
• Ability to obtain and maintain sufficient intellectual property protection for products.
• Compliance with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance.
• Customer concentration.
• Accuracy of estimates regarding expenses, revenue, capital requirements, and need for additional financing.

Future Outlook

The company expects continued growth, driven by its portfolio of differentiated medicines, particularly Jornay PM. It has raised its full-year 2025 guidance for net revenue to $775-$785 million and adjusted EBITDA to $460-$470 million. The company aims to achieve net leverage of less than 1.0x by the end of 2025 and plans to continue expanding its portfolio through disciplined business development while rapidly paying down debt and opportunistically repurchasing shares. Investments in Jornay PM are expected to support near-term growth and drive significant momentum into 2026 and beyond.

Management Comments

• "We delivered another strong quarter of results driven by our portfolio of differentiated medicines and unwavering commitment to patients." Vikram Karnani, President and Chief Executive Officer.
• "Jornay PM prescription growth was further bolstered by the start of the back-to-school season, as both patients and healthcare providers increasingly recognize the unique benefits of Jornay PM." Vikram Karnani, President and Chief Executive Officer.
• "The outstanding performance of Jornay PM, along with sustained growth across our pain portfolio, has led us to raise our 2025 financial guidance." Vikram Karnani, President and Chief Executive Officer.
• "As we move into the fourth quarter and look ahead to 2026, we remain dedicated to supporting patients with serious medical conditions while driving shareholder value through strong commercial execution, strategic business development, and disciplined capital deployment." Vikram Karnani, President and Chief Executive Officer.
• "Net revenue and adjusted EBITDA reached record highs this quarter, driven by strong performance from Jornay PM and our pain portfolio." Colleen Tupper, Chief Financial Officer.
• "We also generated meaningful operating cash flows, further strengthening our financial position." Colleen Tupper, Chief Financial Officer.
• "We continue to execute our capital deployment strategy which balances rapidly paying down debt, opportunistically repurchasing shares, and actively evaluating opportunities to expand our portfolio through business development." Colleen Tupper, Chief Financial Officer.
• "We are on track to achieve our updated guidance, setting a solid foundation for continued growth in 2026." Colleen Tupper, Chief Financial Officer.

Industry Context

Collegium Pharmaceutical operates in the biopharmaceutical sector, focusing on responsible pain management and neuropsychiatry, particularly ADHD. The strong growth of Jornay PM, an ADHD treatment, is notably influenced by seasonal factors like the back-to-school season, highlighting the importance of market timing and patient/provider awareness in this segment. The consistent growth across its pain portfolio, supported by real-world data publications, indicates a competitive landscape where product differentiation and evidence-based benefits are crucial for market penetration and sustained revenue. The company's strategy of leveraging a lead growth driver (Jornay PM) and disciplined capital deployment (debt reduction, share repurchases, business development) is a common approach for established biopharma companies seeking to optimize shareholder value and expand their market presence.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against global industry standards. The focus is on internal performance metrics and growth rates.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and share repurchase programs, indicating potential for increased share price and return on investment.
• Employees: Positive impact from continued growth and expansion, potentially leading to job security and opportunities, especially with the expanded ADHD sales force.
• Customers (patients): Positive impact through continued availability and promotion of differentiated medicines for serious medical conditions like ADHD and pain.
• Healthcare Providers: Increased awareness and utilization of products like Jornay PM, supported by real-world data and expanded sales force engagement.
• Creditors: Positive impact from the company's focus on rapidly paying down debt and improving its net leverage ratio, indicating stronger financial stability.

Next Steps

• Participate in the Jefferies London Healthcare Conference on November 19, 2025.
• Participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025.
• Participate in the Evercore 8th Annual Healthcare Conference on December 4, 2025.
• Continue to invest in Jornay PM to support near-term growth and create significant momentum in 2026 and beyond.
• Increase adoption of Jornay PM in an expanded set of prescribers.
• Raise awareness of Jornay PM among patients and caregivers to drive prescription growth.
• Expand the portfolio through disciplined business development.
• Rapidly pay down debt and opportunistically repurchase shares.
• Maximize and enhance the durability of the pain portfolio to generate durable operating cash flows.

Key Dates

Recommendation

Collegium Pharmaceutical has delivered exceptional Q3 2025 results, marked by record revenues and Adjusted EBITDA, significantly exceeding prior-year performance. The company has raised its full-year 2025 guidance across key financial metrics, signaling robust confidence in its continued growth trajectory. The strong performance of Jornay PM and the pain portfolio, coupled with disciplined capital deployment strategies including debt reduction and substantial share repurchases, demonstrates a well-managed and financially healthy company. The improving net debt to Adjusted EBITDA ratio further strengthens its financial position. These factors collectively present a compelling investment case for a strong buy, indicating significant upside potential for investors.

Keywords

Collegium Pharmaceutical, COLL, Q3 2025 Earnings, Financial Results, Guidance Update, Jornay PM, ADHD, Pain Management, Belbuca, Xtampza ER, Nucynta Franchise, Biopharmaceutical, Pharmaceutical, Revenue Growth, EBITDA, Share Repurchase, Capital Deployment